Endo Health Solutions is extending its makeover with a bolt-on deal, trading $105 million up front for NuPathe to get its hands on the migraine patch Zecuity.
Valeant Pharmaceuticals has added another $250 million deal to its buyout tally, with a $250 million bid to buy Solta Medical, a maker of dermatological treatment devices. And Endo Health Solutions has agreed to pay up to $220 million for NuPathe and its brand-new migraine treatment Zecuity.
GlaxoSmithKline CEO Andrew Witty says he's a "huge bull" on India, despite the ongoing patent-rights tug-of-war between foreign drugmakers and domestic officials. Now, Witty is putting another $1 billion where his mouth is.
After layoffs, a sales strategy revamp and spending cuts, Solta Medical has found a buyer to rescue it from its financial and market woes. The Hayward, CA, maker of aesthetic medical devices will sell itself to Valeant Pharmaceuticals for $250 million in cash.
There's nothing like cold, hard cash in your pocket, and that fact may be enough to derail CFR Pharmaceuticals' takeover bid for South Africa's Adcock Ingram. Adcock's top shareholder has rejected a sweetened cash-and-stock offer from CFR, opening a window for rival bidder Bidvest Group to push its counteroffer through.
When struggling Complete Genomics went up for sale last year, it sparked a fight between rival sequencing superpowers BGI and Illumina that touched on national security and a host of other big issues. BGI ultimately won and has now begun to outline its plans for its $119 million acquisition.
Having acquired Qumas and its electronic regulatory document management capabilities, Accelrys plans to integrate the system with its existing offerings.
Emergent BioSolutions, already the go-to company for anthrax vaccines, will buy Cangene Corp. for about $222 million, adding to its stable of biodefense contracts and picking up a contract manufacturing business that can kick in some additional revenue.
Earlier this fall, Given Imaging faced down restive shareholder Discovery Group, which urged the Israeli maker of the PillCam endoscopic camera to explore a sale. Now that Covidien will snatch up the company for $860 million, the activist investor has decided to move on.
U.K. CRO Quotient Clinical is now the property of private equity outfit Bridgepoint Development Capital, joining the crowd of pharma contractors signing up to be acquired in a fast-consolidating industry.